We investigated the expression of @entity1262 ( @entity1262 ) and metallothionein (MT) in a series of 92 @entity677 and 14 @entity344 ( @entity344 ) with the purpose to expand our knowledge on the biological bases of @entity677 chemo-resistance and to ascertain their significance in @entity1 ' prognosis. @entity1262 expression was more frequent in @entity677 than in GI- @entity11293 (83.7% vs. 21.4%, p<0.001), with no difference between low- and high-risk @entity677 (p=1.000) or low- and high-grade GI- @entity11293 (p=0.538). @entity1262 expression was unrelated to anatomic location (gastric vs. intestinal) in @entity677 (39/45 vs. 35/43, p=0.770) and in GI- @entity11293 (0/2 vs. 2/6, p=1.000). MT expression was non-significantly higher in GI- @entity11293 than in @entity677 (35.7% vs. 14.1%, p=0.060), with no difference between low- and high-risk @entity677 (p=1.000) or low- and high-grade GI- @entity11293 (p=1.000). MT expression was unrelated to the anatomic location (gastric vs. intestinal) in @entity677 (7/45 vs. 6/43) and GI- @entity11293 (0/2 vs. 1/6) (p=1.000 and p=0.1000, respectively). Overall @entity5 -specific survival (p< 0.001) and disease-free survival (p<0.001) were different in @entity677 as compared with GI- @entity11293 , and the number of events was higher in GI- @entity11293 . When the survival analysis took into consideration @entity1262 or MT expression, the overall survival in @entity677 was influenced by the expression of MT (p=0.021) but not by that of @entity1262 (p=0.638). However, in GI- @entity11293 , @entity1262 expression influenced disease-free survival (p=0.050); in addition, it is important to recognize the limited value of these results because of the low number of cases involved in the study. Differential expression of @entity1262 and MT might explain the known variability in response to systemic chemotherapy in these @entity5 . Detection of @entity1262 and MT seems to add certain prognostic value in @entity11293 ( @entity1262 ).

Expression of XXXX and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1262 :: ('5243', 'Gene') :: ['P-GP', 'P-glycoprotein'] @entity677 :: ('MESH:C564650', 'Disease') :: ['GIST'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity344 :: ('MESH:D005767', 'Disease') :: ['GILMS', 'gastrointestinal leiomyosarcomas'] @entity11293 :: ('MESH:C535903', 'Disease') :: ['LMS', 'GIST (MT) or GI-LMS']
@entity1262 :: (5243,Gene) :: ['P-glycoprotein']
